Monday, 24 Feb 2020

You are here

Genicular Artery Embolization to Treat Osteoarthritis Knee Pain

A study from the Journal of Vascular and Interventional Radiology has shown that  knee pain secondary to osteoarthritis (OA) may be effectively treated by selective vascular interruption (embolization) showing efficacy and safety in a small pilot trial. 

In an uncontrolled 20 patient observational study, adults with radiographic knee OA and moderate-to-severe pain refractory to conservative therapy were enlisted to study the effects of  embolization of hyperemic synovial tissue for the treatment of knee pain secondary to osteoarthritis (OA). Genicular artery embolization (GAE) was performed with 75- or 100-μm spherical particles. Patients were assessed magnetic resonance imaging at baseline and at 1 month and also with the Visual Analogue Scale (VAS)  and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline and at 1, 3, and 6 months.

Embolization of at least 1 genicular artery was achieved in all patients. The mean VAS improved from 76 mm ± 14 (baseline) to 29 mm ± 27 at 6-months (P <.01). WOMAC scores also dropped by more than 50% (61 ± 12 to 29 ± 27) at 6-months

Adverse events were limited to short-lived skin discoloration (65%) and 2 patients (10%) developed plantar sensory paresthesia that resolved within 14 days.

While OA has long been considered a degenerative disorder with a minor inflammatory component, research has suggested a prominent role for vascular ischemia and that OA "pain" may reflect "osteo-angina". Selective embolization may be a means of approaching problematic, painful OA of the knee in the future, but more studies are needed. 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

JAK Inhibitors Stimulate Osteoblasts

Science Translational Medicine has a report on how the use of Janus kinase (JAK) inhibitors may boost osteoblasts to battle bone erosions in conditions like rheumatoid arthritis (RA).

JAK inhibitors have been shown in clinical trials to retard the development of bone erosions while controlling RA inflammation and other clinical features.

Hormone Therapy for Postmenopausal Women

The NEJM weighs in on the problem of post-menopausal osteoporosis (OP) and tackles the use of hormonal therapy. The decline in estrogen after menopause may increase risks for osteoporosis, cardiovascular disease, and cognitive decline. The use of hormone replacement therapy (HRT) to obviate these issues may be primarily driven by hot flashes in postmenopausal women.1 Who may benefit from hormone therapy among postmenopausal women?

Knee Replacements Last 25 Years

UK registry reports that greater than 80% of total knee replacements can last for 25 years.

The outcomes regarding the duration and durability of knee arthroplasties is sketchy, with many orthopedists projecting a 15 to 20 year survivial. Hence the need for an appraisal of the data.

Should We Screen Younger Postmenopausal Women for Osteoporosis?

Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.

ACR-Arthritis Foundation Treatment Guidelines for Osteoarthritis

Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee. The ACR periodically updates guidelines to reflect any advances in management added to the literature since the last publication, which in this case was 2012.